Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration.
Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder (PTSD).
Get the full story at our sister site, Drug Delivery Business News.